IL17A and hepatocellular carcinoma: Moreover, IL-17 can inhibit the anti-tumor effects of IFN-γ and up-regulate the expression of the negative feedback regulator PIAS1 by activating the JAK/STAT1 pathway, thereby accelerating HCC development (135).